Lucentis (Ranibizumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Lucentis (ranibizumab) is a prescription drug used to treat a range of eye conditions involving abnormal blood vessel growth in the retina. It is a recombinant monoclonal antibody fragment that works by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for the formation of abnormal blood vessels.

The main forms of Lucentis (ranibizumab) available in the market are single-use prefilled syringes and single-use glass vials. A single-use prefilled syringe is a medical device containing a pre-measured dose of medication, ready for immediate use. Its applications include age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, myopic choroidal neovascularization, and uveitis. Key end-users include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

Tariffs have influenced the Lucentis market by increasing costs for imported biologic substances, prefilled syringe components, and cold chain logistics. These impacts are more visible in regions dependent on imported ophthalmic biologics, particularly asia pacific and latin america. Hospital and clinic procurement costs have increased, affecting treatment affordability. However, tariffs have driven local packaging and distribution partnerships. This supports supply continuity and improves regional market resilience.

The lucentis (ranibizumab) market research report is one of a series of new reports from The Business Research Company that provides lucentis (ranibizumab) market statistics, including lucentis (ranibizumab) industry global market size, regional shares, competitors with a lucentis (ranibizumab) market share, detailed lucentis (ranibizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the lucentis (ranibizumab) industry. This lucentis (ranibizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lucentis (ranibizumab) market size has grown strongly in recent years. It will grow from $3.74 million in 2025 to $3.96 million in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to clinical success in macular degeneration, rising diabetic retinopathy cases, aging population, ophthalmologist adoption, regulatory approvals in eye care.

The lucentis (ranibizumab) market size is expected to see strong growth in the next few years. It will grow to $4.87 million in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growth in retinal disease prevalence, increasing access to eye care services, expansion of biosimilar competition, rising awareness of early diagnosis, technological advances in injection delivery. Major trends in the forecast period include sustained use of anti vegf therapies, rising treatment of retinal vascular disorders, growing preference for intravitreal injections, expansion of ophthalmology specialty clinics, increased focus on vision preservation.

The rising prevalence of eye-related disorders is expected to drive the growth of the Lucentis (ranibizumab) market in the coming years. Eye-related disorders encompass a variety of conditions that affect the eyes and impair their proper functioning. The increasing occurrence of these disorders is attributed to aging, genetic predisposition, unhealthy lifestyle choices such as smoking and poor diet, and environmental factors like prolonged sun exposure or extended digital screen use. Lucentis acts by inhibiting vascular endothelial growth factor (VEGF), a protein that causes abnormal blood vessel growth and leakage in the retina, which is a major contributor to conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). For example, in 2024, the National Eye Institute, a US government agency, projected that 2.2 million Americans will be blind by 2030. Therefore, the growing prevalence of eye-related disorders is fueling the expansion of the Lucentis (ranibizumab) market.

The increase in healthcare spending is also expected to support the growth of the Lucentis (ranibizumab) market. Healthcare spending refers to the total financial resources allocated by individuals, governments, private insurers, and other organizations for healthcare services and products. This increase is driven by an aging population, advancements in medical technologies, rising prevalence of chronic diseases, and higher demand for healthcare services. Greater healthcare spending enhances the accessibility and availability of Lucentis (ranibizumab) by supporting its widespread use in treating retinal conditions like AMD and DME, ensuring healthcare systems can allocate resources for its coverage, reimbursement, and distribution, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, in May 2024, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to 0.9% growth in 2022. The total UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. As a result, rising healthcare spending is driving the growth of the Lucentis (ranibizumab) market.

Key players in the Lucentis (ranibizumab) market are focusing on developing biosimilars to offer more affordable alternatives to the original branded product. Biosimilars are biologic medicines that are highly similar to an already approved reference biologic in structure, efficacy, and safety, with no clinically meaningful differences. For example, in April 2024, Formycon AG, a Germany-based biotechnology company, and Bioeq AG, a Switzerland-based biotechnology company, launched their biosimilar version of Lucentis (ranibizumab), called FYB201, in Canada and Switzerland. Health Canada granted marketing authorization under the name Ranopto, while Swiss Medic approved it as Ranivisio. The approval and launch of FYB201 aim to provide more affordable treatment options for patients with retinal diseases. It works by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that promotes abnormal blood vessel growth in the retina, which can cause swelling, leakage, and vision impairment.

Major companies operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG

North America was the largest region in the lucentis (ranibizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lucentis (ranibizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The lucentis (ranibizumab) market consists of sales of lucentis intravitreal injection and lucentis for biosimilars. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lucentis (Ranibizumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses lucentis (ranibizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lucentis (ranibizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lucentis (ranibizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Single-use Prefilled Syringe; Single-use Glass Vial
• 2) By Application: Age-related Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion; Myopic Choroidal Neovascularization; Uveitis
• 3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Companies Mentioned: F.Hoffmann-La Roche Ltd; Novartis AG
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.